Heart scan AI could predict sudden cardiac death risk in common heart condition

NCT ID NCT07695272

First seen Jul 10, 2026 ยท Last updated Jul 10, 2026

Summary

This study looks at whether detailed analysis of heart MRI images (called radiomics) can better predict life-threatening heart rhythms in people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens. Researchers will also see if the drug mavacamten, which helps relieve obstruction in some HCM patients, leads to changes in these imaging features that might lower risk over time. The goal is to improve current risk prediction tools, which are only moderately accurate.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
mavacamten
What this could lead to
If successful, this could lead to more accurate, personalized risk assessments for sudden cardiac death in people with hypertrophic cardiomyopathy, and show whether mavacamten treatment changes that risk over time.
What could go wrong
This is an observational and exploratory study, not a treatment trial. The radiomics approach is still being tested and may not improve prediction enough to change clinical practice. Results may take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC MYOSIN INHIBITORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centro Cardiologico Monzino; IRCCS

    Milan, Milan, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.